University Hospital of Bellvitge, Biomedical Research Institute of Bellvitge (IDIBELL) University of Barcelona, L' Hospitalet de Llobregat Spain.
Clinic Hospital of Barcelona August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona Spain.
J Am Heart Assoc. 2021 Nov 16;10(22):e022123. doi: 10.1161/JAHA.121.022123. Epub 2021 Nov 3.
Background Early generation drug-eluting stents (DESs) showed a high grade of coronary endothelial dysfunction that was attributed to lack of stent reendothelialization. Endothelium-dependent vasomotor response of current DESs and bioresorbable scaffolds (BRSs) remains unknown. This study sought to assess the device-related endothelial function of current devices and to correlate neointima healing with endothelial function. Methods and Results A total of 206 patients from 4 randomized trials treated with the durable-polymer everolimus-eluting Xience (n=44), bioresorbable-polymer sirolimus-eluting Orsiro (n=35), polymer-free biolimus-eluting Biofreedom (n=24), bioactive endothelial-progenitor cell-capturing sirolimus-eluting Combo DES (n=25), polymer-based everolimus-eluting Absorb (n=44), and Mg-based sirolimus-eluting Magmaris BRS (n=34) underwent endothelium-dependent vasomotor tests and optical coherence tomography imaging, as per protocol, at follow-up. Crude vasomotor responses of distal segments to low-dose acetylcholine (10 mol/L) were different between groups: bioresorbablepolymer DEShad the worst (-8.4%±12.6%) and durable-polymer DES had the most physiologic (-0.4%±11.8%; =0.014). High-dose acetylcholine (10 mol/L) showed similar responses between groups (ranging from -10.8%±11.6% to -18.1%±15.4%; =0.229). Device healing was different between devices. Uncovered struts ranged from 6.3%±7.1% (bioresorbable-polymer DES) to 2.5%±4.5% (bioactive DES; =0.056). In multivariate models, endothelium-dependent vasomotor response was associated with age, bioresorbable-polymer DES, and angiographic lumen loss, but not with strut coverage nor plaque type. Endothelial dysfunction (defined as ≥4% vasoconstriction) was observed in 46.6% of patients with low-dose and 68.9% with high-dose acetylcholine, without differences between groups. Conclusions At follow-up, endothelial dysfunction was frequently observed in distal segments treated with current stents without remarkable differences between devices. Although neointima healing was different between devices, poor healing was not associated with endothelial dysfunction.
背景 第一代药物洗脱支架(DES)显示出较高水平的冠状动脉内皮功能障碍,这归因于支架再内皮化的缺乏。目前 DES 和生物可吸收支架(BRS)的内皮依赖性血管舒缩反应仍不清楚。本研究旨在评估目前器械相关的内皮功能,并将新生内膜愈合与内皮功能相关联。
方法和结果 共有 206 名来自 4 项随机试验的患者接受了耐用聚合物依维莫司洗脱 Xience(n=44)、生物可吸收聚合物西罗莫司洗脱 Orsiro(n=35)、无聚合物比伐卢定洗脱 Biofreedom(n=24)、生物活性内皮祖细胞捕获西罗莫司洗脱 Combo DES(n=25)、聚合物基依维莫司洗脱 Absorb(n=44)和 Mg 基西罗莫司洗脱 Magmaris BRS(n=34)的治疗,根据方案在随访时进行内皮依赖性血管舒缩试验和光学相干断层扫描成像。各组之间远端节段对低剂量乙酰胆碱(10 mol/L)的原始血管舒缩反应不同:生物可吸收聚合物 DES 的反应最差(-8.4%±12.6%),而耐用聚合物 DES 的反应最接近生理状态(-0.4%±11.8%;=0.014)。高剂量乙酰胆碱(10 mol/L)显示各组之间的反应相似(范围为-10.8%±11.6%至-18.1%±15.4%;=0.229)。器械愈合在不同器械之间存在差异。未覆盖的支架范围从 6.3%±7.1%(生物可吸收聚合物 DES)到 2.5%±4.5%(生物活性 DES;=0.056)。多元模型显示,内皮依赖性血管舒缩反应与年龄、生物可吸收聚合物 DES 和血管造影管腔丢失相关,但与支架覆盖率或斑块类型无关。在低剂量和高剂量乙酰胆碱中,分别有 46.6%和 68.9%的患者出现内皮功能障碍(定义为≥4%的血管收缩),但各组之间无差异。
结论 随访时,目前的支架治疗远端节段常出现内皮功能障碍,不同器械之间无明显差异。尽管新生内膜愈合在不同器械之间存在差异,但愈合不良与内皮功能障碍无关。